SCHEMBL2352257

SCHEMBL2352257

COc1cc(OC(=O)c2cccnc2)ccc1-c1ccc2c(c1COC(=O)c1cccc(F)c1)C(C)=CC(C)(C)N2

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.59
TP53 P04637 2/20 0.59
MAPT P10636 2/20 0.59
HTT P42858 2/20 0.59
NPSR1 Q6W5P4 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
HSD17B10 Q99714 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
NR3C1 P04150 10/20 0.39
PGR P06401 5/20 0.39
AR P10275 3/20 0.39
NR3C2 P08235 2/20 0.39
KMT2A Q03164 4/20 0.38
POLB P06746 1/20 0.38
ATM Q13315 1/20 0.38
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1782269 0.91 MAPT (0.62) LMNATP53MAPTHTTNPSR1
SCHEMBL5034924 0.91 TDP1 (0.52) LMNATP53MAPTHTTNPSR1
SCHEMBL1781590 0.91 MAPT (0.61) LMNATP53MAPTHTTNPSR1
SCHEMBL1314639 0.88 LMNA (0.58) LMNATP53MAPTHTTNPSR1
SCHEMBL2345968 0.88 TP53 (0.56) LMNATP53MAPTHTTNPSR1
SCHEMBL1780626 0.87 LMNA (0.59) LMNATP53MAPTHTTNPSR1
SCHEMBL448668 0.87 NR3C1 (0.46) NR3C1PGRARNR3C2ESR1
SCHEMBL1782503 0.86 LMNA (0.57) LMNATP53MAPTHTTNPSR1
SCHEMBL1781535 0.86 LMNA (0.40) LMNATP53MAPTHTTNPSR1
SCHEMBL2350465 0.86 NR3C1 (0.43) NR3C1PGRARNR3C2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563551-B2 Method for preventing or treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-10-22 US disclosed
US-8563551-B2 Method for preventing or treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-10-22 US disclosed
US-8563551-B2 Method for preventing or treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-10-22 US disclosed
EP-2085389-B1 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO LTD (JP) 2012-09-26 EP disclosed
US-20110263600-A1 Method for preventing or treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. 2011-10-27 US disclosed
US-20110263600-A1 Method for preventing or treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. 2011-10-27 US disclosed
US-20110263600-A1 Method for preventing or treating a disease related to the glucocorticoid receptor SANTEN PHARMACEUTICAL CO., LTD. 2011-10-27 US disclosed
US-8008497-B2 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-08-30 US disclosed
US-8008497-B2 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-08-30 US disclosed
US-8008497-B2 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-08-30 US disclosed
US-20090298826-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-03 US disclosed
US-20090298826-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-03 US disclosed
US-20090298826-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-03 US disclosed
EP-2085389-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298826-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS NR3C1, NR3C2, NR5A1 LMNA 4460/4885TP53 4197/4885MAPT 4861/4885
US-20110263600-A1 Method for preventing or treating a disease related to the glucocorticoid receptor NR3C1, NR3C2, MC2R LMNA 2023/4885TP53 4044/4885MAPT 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.